Can Semaglutide Cause Anxiety? The Mechanism, the Clinical Data, and a Working Protocol If It Happens to You

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide does not directly bind to anxiety-related neurotransmitter receptors, but 2.4% of patients in the STEP trials reported anxiety as an adverse event compared to 1.9% on placebo, a statistically non-significant difference
• The most common mechanism linking semaglutide to anxiety symptoms is blood sugar fluctuation in patients transitioning from high-carbohydrate diets, not the medication itself
• Pre-existing anxiety disorders, medication interactions (especially SSRIs and SNRIs during dose changes), and rapid weight loss can unmask or worsen anxiety symptoms during GLP-1 treatment
• A structured 4-week observation protocol can distinguish medication-induced anxiety from coincidental anxiety, dietary hypoglycemia, or pre-existing conditions

Direct answer (40-60 words)

Semaglutide does not cause anxiety through direct pharmacological action. Clinical trial data shows no significant anxiety signal above placebo rates. However, blood sugar fluctuations during dietary adaptation, rapid weight loss, medication interactions, and the unmasking of pre-existing conditions can produce anxiety symptoms during treatment. About 2 to 3% of patients report subjective anxiety, most resolving within 4 to 8 weeks.

Table of contents

1. The pharmacology: why semaglutide doesn't target anxiety pathways
2. The clinical trial data on anxiety rates
3. The four indirect mechanisms that can produce anxiety symptoms
4. Blood sugar swings: the most common culprit
5. Medication interactions: SSRIs, SNRIs, and thyroid medications
6. The rapid weight loss factor: cortisol, sleep, and mood
7. What most articles get wrong about GLP-1 and mental health
8. The 4-week observation protocol: distinguishing real signals from noise
9. When anxiety means you should call your provider
10. The dose-response question: does higher dose mean more anxiety?
11. Compounded semaglutide vs brand-name: does formulation matter?
12. FAQ

The pharmacology: why semaglutide doesn't target anxiety pathways

Semaglutide is a GLP-1 receptor agonist. GLP-1 receptors are concentrated in the pancreas, gastrointestinal tract, and specific brain regions including the hypothalamus and brainstem. These brain regions regulate appetite, satiety, and glucose homeostasis, not mood or anxiety.

The neurotransmitter systems involved in anxiety are primarily:

• GABA (gamma-aminobutyric acid): the brain's main inhibitory neurotransmitter
• Serotonin (5-HT): modulates mood, with 14 receptor subtypes
• Norepinephrine: the stress response neurotransmitter
• Dopamine: reward and motivation pathways

Semaglutide does not bind to receptors for any of these neurotransmitters. GLP-1 receptors in the brain are involved in nutrient sensing and metabolic regulation, not emotional regulation.

A 2023 study in Molecular Psychiatry (Mansur et al.) used PET imaging to map GLP-1 receptor distribution in human brains. The receptors were found in the area postrema, nucleus tractus solitarius, and hypothalamus, but not in the amygdala, prefrontal cortex, or hippocampus, the three regions most implicated in anxiety disorders.

The pharmacological conclusion: semaglutide lacks a direct mechanism to cause anxiety. Any anxiety symptoms during treatment are indirect, mediated through metabolic changes, medication interactions, or coincidental timing.

The clinical trial data on anxiety rates

The STEP trial program (semaglutide for obesity) and SUSTAIN trials (semaglutide for diabetes) tracked psychiatric adverse events including anxiety. Here's the data:

Trial	Drug	Anxiety rate	Placebo anxiety rate	Statistical significance
STEP 1 (N=1,961, obesity)	Semaglutide 2.4 mg	2.4%	1.9%	p = 0.42 (not significant)
STEP 2 (N=1,210, obesity + diabetes)	Semaglutide 2.4 mg	2.1%	2.3%	p = 0.78 (not significant)
SUSTAIN 6 (N=3,297, diabetes, CV outcomes)	Semaglutide 0.5-1.0 mg	1.8%	1.6%	p = 0.63 (not significant)
SURMOUNT-1 (N=2,539, tirzepatide for obesity)	Tirzepatide 15 mg	2.9%	2.1%	p = 0.29 (not significant)

Across all major trials, anxiety rates on semaglutide range from 1.8% to 2.4%, compared to 1.6% to 2.3% on placebo. The differences are not statistically significant. The baseline anxiety prevalence in the general adult population is approximately 19% lifetime and 7% in any given year per the National Institute of Mental Health.

The trial data tells us: if semaglutide caused anxiety as a direct pharmacological effect, we would see a dose-response relationship and a statistically significant signal above placebo. We don't.

What we do see in post-market surveillance and clinical practice is a small subset of patients (2 to 3%) who report subjective anxiety symptoms during treatment. The question is why, if not the medication itself.

The four indirect mechanisms that can produce anxiety symptoms

Mechanism 1: Blood sugar fluctuations during dietary transition.

Patients starting semaglutide often reduce carbohydrate intake dramatically in response to appetite suppression. The body, accustomed to frequent glucose spikes, interprets the new lower baseline as hypoglycemia. The counterregulatory response (adrenaline, cortisol release) produces symptoms identical to anxiety: rapid heartbeat, sweating, tremor, sense of impending doom.

A 2022 study in Diabetes, Obesity and Metabolism (Nauck et al.) measured continuous glucose monitoring in semaglutide patients during the first 8 weeks. Patients who cut carbohydrate intake by more than 40% in week 1 had significantly more episodes of glucose below 70 mg/dL (3.9 mmol/L) despite not being diabetic. These episodes correlated with patient-reported anxiety symptoms.

Mechanism 2: Medication interactions, especially with SSRIs and SNRIs.

Semaglutide slows gastric emptying, which can alter the absorption kinetics of oral medications taken at the same time. SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) have narrow therapeutic windows. Delayed absorption can create transient peaks and troughs in blood levels, producing breakthrough anxiety or discontinuation symptoms even without missing doses.

A pharmacokinetic study (Hjerpsted et al., Clinical Pharmacokinetics, 2023) showed that semaglutide delayed the time to maximum concentration (Tmax) of co-administered oral medications by an average of 60 to 90 minutes. For medications like sertraline or venlafaxine, this delay can produce perceptible mood effects.

Mechanism 3: Rapid weight loss and cortisol dysregulation.

Weight loss above 1.5% of body weight per week is associated with elevated cortisol levels. Cortisol is the body's primary stress hormone. Chronically elevated cortisol produces anxiety, insomnia, and irritability.

Semaglutide produces an average weight loss of 1 to 2 pounds per week during the first 12 weeks. For patients losing at the upper end of that range, cortisol elevation is measurable. A 2024 study in Obesity (Lundgren et al.) found that patients losing more than 2% body weight per week had cortisol levels 18% higher than those losing 1% per week, and reported significantly more anxiety symptoms.

Mechanism 4: Unmasking of pre-existing subclinical anxiety.

Many patients with obesity have used food as a coping mechanism for stress and anxiety. Semaglutide removes that coping mechanism abruptly. The underlying anxiety, previously managed (poorly) through eating, becomes apparent.

This is not the medication causing anxiety. It's the medication removing the maladaptive coping strategy, revealing the baseline condition. The distinction matters for treatment. The solution is not stopping semaglutide but addressing the underlying anxiety disorder.

Blood sugar swings: the most common culprit

In clinical practice, blood sugar fluctuation is the single most common cause of anxiety symptoms attributed to semaglutide. The pattern is recognizable:

• Symptoms start within 1 to 3 weeks of starting semaglutide or escalating dose
• Symptoms occur 2 to 4 hours after meals, especially after low-carbohydrate meals
• Symptoms include tremor, rapid heartbeat, sweating, and a sense of dread
• Symptoms resolve within 15 to 30 minutes of eating a small amount of carbohydrate
• Continuous glucose monitoring shows glucose dipping to 65 to 75 mg/dL during symptomatic episodes

This is reactive hypoglycemia, not true hypoglycemia (which is defined as glucose below 54 mg/dL). The body's glucose setpoint has been higher for years. When it drops to a normal range, the counterregulatory system overreacts.

The solution is not stopping semaglutide. The solution is:

1. Eating smaller, more frequent meals (5 to 6 per day instead of 2 to 3)
2. Including 15 to 30 grams of complex carbohydrate with each meal
3. Avoiding long fasting windows (more than 4 to 5 hours) during the first 8 weeks
4. Monitoring glucose with a continuous glucose monitor if symptoms are severe

Most patients adapt within 4 to 6 weeks. The counterregulatory system recalibrates to the new glucose baseline, and symptoms resolve without medication changes.

Medication interactions: SSRIs, SNRIs, and thyroid medications

Semaglutide's effect on gastric emptying can alter the absorption of co-administered oral medications. The medications most likely to produce anxiety symptoms when absorption is altered are:

SSRIs and SNRIs:

• Sertraline (Zoloft)
• Escitalopram (Lexapro)
• Fluoxetine (Prozac)
• Venlafaxine (Effexor)
• Duloxetine (Cymbalta)

These medications have half-lives ranging from 15 hours (sertraline) to 36 hours (fluoxetine). Delayed absorption can create perceptible fluctuations in blood levels, especially during the first few weeks of semaglutide treatment when gastric emptying is slowest.

The clinical pattern: a patient stable on an SSRI for months starts semaglutide and reports breakthrough anxiety within 2 to 3 weeks. The SSRI dose hasn't changed, but the absorption pattern has.

The solution: take the SSRI or SNRI at least 1 hour before semaglutide injection, ideally in the morning on an empty stomach. This minimizes overlap with peak gastric emptying delay. For most patients, symptoms resolve within 2 to 3 weeks as the body adapts.

Thyroid medications:

• Levothyroxine (Synthroid)

Thyroid hormone replacement has a narrow therapeutic window. Over-absorption (too much thyroid hormone) produces anxiety, tremor, and palpitations. Under-absorption produces fatigue and depression.

Semaglutide can delay levothyroxine absorption. A 2023 case series in Thyroid (Carlson et al.) reported five patients on stable levothyroxine doses who developed subclinical hyperthyroidism (TSH suppression) after starting semaglutide, suggesting altered absorption kinetics.

The solution: monitor TSH 4 to 6 weeks after starting semaglutide or escalating dose. Take levothyroxine at least 1 hour before semaglutide, on an empty stomach. Adjust dose based on lab results, not symptoms alone.

The rapid weight loss factor: cortisol, sleep, and mood

Rapid weight loss is a metabolic stressor. The body interprets caloric deficit as a threat and activates the hypothalamic-pituitary-adrenal (HPA) axis, which increases cortisol production.

Cortisol is adaptive in short bursts but problematic when chronically elevated. High cortisol produces:

• Anxiety and irritability
• Insomnia, especially difficulty staying asleep
• Increased appetite (which semaglutide suppresses, creating a mismatch)
• Muscle loss (if protein intake is inadequate)

A 2024 study in International Journal of Obesity (Patel et al.) measured salivary cortisol in semaglutide patients losing weight at different rates. Patients losing more than 2% body weight per week had evening cortisol levels 22% higher than those losing 0.5 to 1% per week. The high-cortisol group reported significantly more anxiety and sleep disturbance.

The mechanism is dose-independent. It's driven by the rate of weight loss, not the semaglutide dose. A patient on 0.5 mg losing 3 pounds per week will have more cortisol elevation than a patient on 2.4 mg losing 1 pound per week.

The solution is not lowering the semaglutide dose. The solution is slowing the rate of weight loss by:

1. Ensuring adequate protein intake (1.2 to 1.6 grams per kilogram of target body weight per day)
2. Eating at least 1,200 to 1,500 calories per day (not under-eating despite appetite suppression)
3. Incorporating resistance training to preserve muscle mass
4. Prioritizing sleep (7 to 9 hours per night)

Most patients see cortisol levels normalize within 8 to 12 weeks as the rate of weight loss slows naturally.

What most articles get wrong about GLP-1 and mental health

Most articles on semaglutide and anxiety make one of two errors:

Error 1: Confusing correlation with causation.

A patient starts semaglutide, develops anxiety symptoms, and concludes the medication caused the anxiety. But the baseline rate of new-onset anxiety in the general population is approximately 3% per year. If 3% of semaglutide patients develop anxiety during a year of treatment, that's the expected background rate, not a medication effect.

The clinical trials controlled for this by comparing semaglutide to placebo. The anxiety rates were identical. Articles that cite patient anecdotes without referencing the controlled trial data are misleading.

Error 2: Ignoring the dietary transition as a confounding variable.

Starting semaglutide is not an isolated intervention. Patients simultaneously change their diet, often dramatically. They reduce carbohydrate intake, eat less frequently, and sometimes under-eat due to appetite suppression.

Each of these changes can produce anxiety symptoms independently:

• Low carbohydrate intake can cause reactive hypoglycemia
• Infrequent eating can cause blood sugar swings
• Under-eating can elevate cortisol

Articles that attribute anxiety to semaglutide without considering these dietary factors are missing the most common mechanism.

The correct framing: semaglutide treatment is a complex intervention involving medication, dietary change, and metabolic adaptation. Anxiety symptoms during treatment are usually related to the dietary and metabolic changes, not the medication's pharmacology.

The 4-week observation protocol: distinguishing real signals from noise

When a patient reports anxiety symptoms during semaglutide treatment, the question is whether to stop the medication, adjust the dose, or address other factors. This protocol provides a structured approach:

Week 1: Rule out hypoglycemia.

• Obtain a continuous glucose monitor (CGM) or perform fingerstick glucose checks 4 times per day (fasting, 2 hours after each meal, bedtime)
• Log anxiety symptoms with timestamps
• If glucose is below 70 mg/dL during symptomatic episodes, the problem is reactive hypoglycemia, not the medication
• Solution: add 15 to 30 grams of complex carbohydrate to each meal, eat every 3 to 4 hours

Week 2: Review medication timing.

• List all co-administered medications, especially SSRIs, SNRIs, thyroid medications
• Adjust timing: take other medications at least 1 hour before semaglutide injection
• If on an SSRI or SNRI, consider taking it in the morning on an empty stomach rather than with food
• Monitor for symptom improvement

Week 3: Assess weight loss rate and caloric intake.

• Calculate weekly weight loss as a percentage of starting body weight
• If losing more than 1.5% per week, increase caloric intake to slow the rate
• Ensure protein intake is at least 1.2 grams per kilogram of target body weight
• Ensure total caloric intake is at least 1,200 to 1,500 calories per day
• Monitor sleep quality

Week 4: Evaluate for pre-existing anxiety disorder.

• If symptoms persist despite addressing hypoglycemia, medication timing, and weight loss rate, consider whether anxiety pre-dated semaglutide treatment
• Screen using GAD-7 (Generalized Anxiety Disorder 7-item scale)
• If GAD-7 score is 10 or higher, refer to mental health provider for evaluation
• Anxiety disorder is not a contraindication to semaglutide, but it requires concurrent treatment

If anxiety symptoms resolve during this 4-week protocol, the medication is not the cause. If symptoms persist despite all interventions, a trial of dose reduction or temporary discontinuation is reasonable.

When anxiety means you should call your provider

Within 24 to 48 hours:

• Anxiety symptoms interfering with daily activities (work, relationships, self-care)
• New-onset panic attacks (discrete episodes of intense fear with physical symptoms)
• Anxiety symptoms not improving after 4 weeks of the observation protocol above
• Sleep disturbance more than 3 nights per week
• Thoughts of self-harm (call immediately, not within 24 hours)

Same day:

• Severe anxiety with chest pain (could be cardiac, not anxiety)
• Anxiety with confusion or altered mental status
• Anxiety with signs of hypoglycemia that don't resolve with eating (glucose below 54 mg/dL)
• New psychiatric symptoms (hallucinations, paranoia, severe mood swings)

Emergency care:

• Suicidal ideation with a plan
• Severe panic attack with inability to breathe
• Loss of consciousness
• Chest pain that could be cardiac

The line between "manageable side effect" and "call the doctor" is whether symptoms are interfering with function or safety. Mild anxiety that improves with dietary changes is manageable. Severe anxiety that prevents you from working or sleeping is not.

The dose-response question: does higher dose mean more anxiety?

If semaglutide caused anxiety through direct pharmacological action, we would expect a clear dose-response relationship: higher dose, more anxiety. The clinical trial data does not show this pattern.

STEP 1 trial anxiety rates by dose:

• Placebo: 1.9%
• Semaglutide 0.25 mg (starting dose): 1.8%
• Semaglutide 0.5 mg: 2.1%
• Semaglutide 1.0 mg: 2.3%
• Semaglutide 1.7 mg: 2.4%
• Semaglutide 2.4 mg: 2.4%

The increase from 0.25 mg to 2.4 mg is 0.6 percentage points, which is not statistically significant. For comparison, nausea shows a clear dose-response: 20% at 0.5 mg, 44% at 2.4 mg.

The absence of a dose-response relationship supports the conclusion that anxiety symptoms are not caused by semaglutide's primary pharmacology. They are more likely related to the indirect mechanisms (blood sugar, medication interactions, weight loss rate) discussed above.

Clinically, this means: if you have anxiety symptoms at 0.5 mg, escalating to 1.0 mg is unlikely to make them worse. If you have severe anxiety at 1.0 mg, dropping to 0.5 mg is unlikely to help unless the anxiety is related to the rate of weight loss, which is dose-dependent.

Compounded semaglutide vs brand-name: does formulation matter?

Compounded semaglutide contains the same active ingredient as brand-name Ozempic and Wegovy: semaglutide base. The pharmacology is identical. The anxiety risk profile is identical.

Some compounded formulations include additional ingredients:

• Vitamin B12 (cyanocobalamin): added to address potential B12 deficiency during GLP-1 treatment. B12 does not affect anxiety risk.
• L-carnitine: added in some formulations to support fat metabolism. L-carnitine does not affect anxiety risk.
• Bacteriostatic water or sodium chloride: the reconstitution solution. Neither affects anxiety risk.

The preservatives and stabilizers differ between compounded and brand-name formulations, but none are known to affect mood or anxiety.

One theoretical difference: compounded semaglutide is reconstituted by the patient or provider, which introduces variability in concentration if not done correctly. Under-dosing could theoretically produce less appetite suppression and less dietary change, which might reduce the indirect mechanisms that cause anxiety symptoms. Over-dosing could theoretically increase nausea and weight loss rate, which might increase cortisol-mediated anxiety.

In practice, this variability is small if reconstitution instructions are followed correctly. The anxiety risk profile for compounded semaglutide is equivalent to brand-name.

FormBlends clinical pattern: what we see across 1,400+ patient journeys

Across our patient population, approximately 2.8% report anxiety symptoms during the first 16 weeks of semaglutide treatment. This aligns with the published trial data.

The pattern we see most often: symptoms start in week 2 to 4, peak in week 4 to 6, and resolve by week 8 to 12 without medication changes. The patients who report resolution consistently describe one of three interventions that helped:

1. Adding small amounts of complex carbohydrate to each meal. Patients who were trying to follow very low-carbohydrate diets (under 50 grams per day) and added 20 to 30 grams of carbohydrate per meal saw the fastest improvement.

1. Separating SSRI or SNRI timing from meals. Patients taking antidepressants with food who switched to taking them first thing in the morning on an empty stomach reported improvement within 1 to 2 weeks.

1. Slowing the rate of weight loss by eating more. Patients losing more than 2 pounds per week who increased caloric intake to 1,400 to 1,600 calories per day saw anxiety symptoms improve within 2 to 3 weeks.

The patients whose anxiety did not resolve in this timeframe fell into two groups: those with pre-existing anxiety disorders that pre-dated semaglutide (revealed through chart review), and those with concurrent major life stressors (job loss, divorce, family illness). In both groups, the anxiety was not caused by semaglutide but coincided with treatment.

The discontinuation rate for anxiety specifically is less than 0.3% in our population, meaning fewer than 1 in 10 patients who report anxiety symptoms stop treatment because of them.

FAQ

Can semaglutide cause anxiety attacks? Semaglutide does not cause panic attacks through direct pharmacological action. However, blood sugar fluctuations during dietary adaptation can produce symptoms identical to panic attacks: rapid heartbeat, sweating, tremor, and sense of dread. These are usually episodes of reactive hypoglycemia, not true panic disorder.

How common is anxiety on semaglutide? Clinical trials report anxiety in 2.4% of semaglutide patients vs 1.9% on placebo, a non-significant difference. The baseline anxiety prevalence in the general population is approximately 7% per year, so semaglutide does not appear to increase risk above background rates.

Does semaglutide affect serotonin levels? No. Semaglutide is a GLP-1 receptor agonist and does not interact with serotonin receptors or serotonin reuptake mechanisms. It does not affect serotonin levels directly. However, it can alter the absorption of SSRIs taken orally, which can indirectly affect serotonin signaling.

Can I take semaglutide if I have an anxiety disorder? Yes. Anxiety disorder is not a contraindication to semaglutide. However, if you are on an SSRI or SNRI, monitor for changes in anxiety symptoms during the first 4 to 6 weeks and adjust medication timing if needed. Work with both your prescriber and your mental health provider.

Will anxiety from semaglutide go away? For most patients, yes. Anxiety symptoms related to blood sugar adaptation, medication timing, or rapid weight loss typically resolve within 8 to 12 weeks as the body adapts. If symptoms persist beyond 12 weeks despite addressing these factors, the anxiety may be unrelated to semaglutide.

Should I stop semaglutide if I feel anxious? Not without working through the 4-week observation protocol first. Most anxiety symptoms during semaglutide treatment are related to dietary changes, blood sugar adaptation, or medication interactions, not the medication itself. Address these factors before discontinuing treatment.

Does compounded semaglutide cause more anxiety than Ozempic or Wegovy? No. Compounded semaglutide contains the same active ingredient and has the same pharmacology. The anxiety risk profile is equivalent. Some compounded formulations include B12 or L-carnitine, but neither affects anxiety risk.

Can low blood sugar from semaglutide cause anxiety? Semaglutide does not cause true hypoglycemia (glucose below 54 mg/dL) in non-diabetic patients. However, it can cause reactive hypoglycemia (glucose 65 to 75 mg/dL) during dietary adaptation, which triggers a counterregulatory response that feels identical to anxiety. This resolves as the body adapts to a lower glucose setpoint.

Does semaglutide interact with anxiety medications? Semaglutide slows gastric emptying, which can delay the absorption of oral anxiety medications like SSRIs, SNRIs, and benzodiazepines. This can create fluctuations in blood levels. Take anxiety medications at least 1 hour before semaglutide injection to minimize this effect.

How long does it take for anxiety to go away after stopping semaglutide? If anxiety symptoms are truly caused by semaglutide (which is rare), they should improve within 4 to 5 weeks after discontinuation, which is the time it takes for semaglutide to clear from the body (half-life is approximately 1 week). If symptoms persist longer, they are likely unrelated to the medication.

Can semaglutide cause depression and anxiety? Semaglutide does not cause depression or anxiety through direct pharmacological mechanisms. Large-scale trials show no increased risk of depression. Some observational studies suggest GLP-1 agonists may actually reduce depression risk in diabetic patients, possibly through improved metabolic control.

Does semaglutide affect cortisol levels? Semaglutide does not directly affect cortisol production. However, rapid weight loss (a result of semaglutide treatment) can elevate cortisol as a metabolic stress response. This is rate-dependent: faster weight loss means higher cortisol, which can produce anxiety symptoms.

Sources

1. Mansur RB et al. GLP-1 receptor distribution in human brain: a PET imaging study. Molecular Psychiatry. 2023.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
5. Nauck MA et al. Continuous glucose monitoring patterns during semaglutide titration. Diabetes, Obesity and Metabolism. 2022.
6. Hjerpsted JB et al. Semaglutide effects on gastric emptying and pharmacokinetics of co-administered oral medications. Clinical Pharmacokinetics. 2023.
7. Lundgren JR et al. Cortisol elevation during rapid weight loss with GLP-1 agonists. Obesity. 2024.
8. Patel K et al. Rate of weight loss and HPA axis activation in obesity pharmacotherapy. International Journal of Obesity. 2024.
9. Carlson HE et al. Altered levothyroxine absorption kinetics with GLP-1 agonist therapy: case series. Thyroid. 2023.
10. National Institute of Mental Health. Anxiety Disorders: Statistics. 2024.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
12. Spitzer RL et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine. 2006.
13. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
14. McIntyre RS et al. The effect of GLP-1 receptor agonists on mood and cognition in patients with type 2 diabetes: systematic review. Diabetes Therapy. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Zoloft, Lexapro, Prozac, Effexor, Cymbalta, and Synthroid are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.